Credit Rating- Others

13 August 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Intimation regarding withdrawal of Credit Ratings assigned by CRISIL Ratings Limited Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the request of the Company, CRISIL Ratings Limited, vide its letter dated 12 August 2026 (enclosed), has withdrawn the credit ratings assigned to certain lower-limit facilities of the Company. The aforesaid facilities are adequately covered under the credit ratings assigned by India Ratings and Research Private Limited ("India Ratings") in respect of the Company's higher-limit credit facilities. The Company continues to maintain credit ratings from India Ratings and such ratings remain valid and in force. Accordingly, the withdrawal of the aforesaid CRISIL ratings does not have any impact on the Company's existing credit facilities or borrowing arrangements. This is for your information and record. Thanking You. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: a/a Crisil Ratings Rating Rationale August 12, 2026 I Mumbai Cohance Lifesciences Limited Issuer not cooperating, based on best-available information; Ratings migrated to 'Crisil 88/Stable/Crisil A4+ Issuer not cooperating'; Ratings Withdrawn Rating Action Regulator Of Total Bank Loan Facilities Rated Rs.72.5 Crore Instrument Crisil BB/Stable (ISSUER NOT COOPERATING*; Long Term Rating Migrated from 'Crisil AA-/Positive'; Rating RBI Withdrawn) Crisil A4+ (ISSUER NOT COOPERATING*; Short Term Rating RBI Migrated from 'Crisil A1+'; Rating Withdrawn) .. . . . . Note: None of the Directors on Cnsil Ratings L1m1ted's Board are members of rating committee and thus do not part1c1pate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings. 1 crore = 10 million Refer to Annexure for Details of Instruments & Bank Facilities *Issuer did not cooperate; based on best-available information Please note that the rating(s) are based on best available information with the credit rating agency: the entity whose debt is being published via this rating rationale did not provide the requisite information needed to conduct the rating exercise or did not provide the No Default Statements (NDS) for the last three months and is therefore classified as 'non cooperative'. Non-cooperation by issuer Crisil Ratings has been consistently following up with Cohance Lifesciences Limited (CLL) for obtaining information through letters and emails dated July 24, 2026, July 30, 2026 and August 05, 2026 among others, apart from telephonic communication. However, the issuer has remained non cooperative. Investors, lenders and all other market participants should exercise due caution with reference to the ratings assigned/reviewed with the suffix 'Issuer not cooperating' as the ratings are arrived at without any management interaction and based on best-available or limited or dated information on the company. Such non-cooperation by a rated entity may be a result of deterioration in its credit risk profile. These ratings with 'Issuer not cooperating' suffix lack a forward looking component. Detailed rationale Despite repeated attempts to engage with the management, Crisil Ratings failed to receive any information on either the financial performance or strategic intent of CLL, which restricts the ability of Crisil Ratings to take a forward-looking view on the credit quality of the entity. Crisil Ratings believes that rating action on CLL is consistent with 'Assessing Information Adequacy Risk'. Therefore, on account of inadequate information and lack of management cooperation, Crisil Ratings has migrated its ratings on the bank facilities of CLL to 'Crisil BB/Stable/Crisil A+ Issuer not cooperating' from 'Crisil M-/Positive/Crisil A 1+ '. Crisil Ratings has also taken note of the company's performance in fiscal 2026, during which it reported consolidated income of Rs 2,302.64 crore and net profit of Rs 150.12 crore. Furthermore, the company announced its results for the first quarter of fiscal 2027, reporting a total consolidated income of Rs 434.51 crore and net loss of Rs 45.19 crore, compared with consolidated income of Rs 563.48 crore and net profit of Rs 46.40 crore in the corresponding quarter of the previous fiscal. Crisil Ratings has additionally noted the company's disclosure regarding the five observations issued by the USFDA in Form FDA 483 following the recently concluded inspection of its manufacturing facility at Pashamylaram, Hyderabad. Crisil Ratings has withdrawn its ratings on the bank facilities of CLL on the request of the company and after receiving no objection certificate from the banks. The rating action is in line with the Crisil Ratings policy on withdrawal of its rating on bank loan facilities. Analytical approach Crisil Ratings has combined the business and financial risk profiles of CLL with its subsidiaries; Cohance Pharma Inc, Sapala Organics Pvt Ltd and NJ Bio Inc. This is because these companies, collectively referred to as the Cohance group, have a common management team, are in similar lines of business, and have operational links and fungible cash flow. Please refer Annexure -List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation. About the groue Incorporated in November 2018, CLL is a biopharma company specialising in new chemical entity-based contract research and manufacturing services for global life science companies. CLL is among the top five players in India who supply high end intermediaries to innovators. The company got listed on the Bombay Stock Exchange and National Stock Exchange on March 09, 2020. The management of the group has changed with acquisition of significant stake of 50.1 % of CLL by Berhyanda Ltd (fully owned subsidiary of Advent International) as part of its strategy to build a leading end-to-end contract development and manufacturing organisation (COMO) and merchant active pharmaceutical ingredient player servicing the pharmaceutical and specialty chemical markets Cohance Pharma Inc is a wholly owned subsidiary of CLL. It is a special purpose vehicle for undertaking various business opportunities in the pharma industry. Suven Pharma Inc has 7% stake in Raisin Aggregator LP, which is a New Jersey, USA based pharma company. Sapala Organics Pvt Ltd (SOPL) is a Hyderabad-based COMO founded in 2005 by Dr P Yella Reddy who has extensive experience in nucleic acid chemistry. On July 12, 2024; CLL acquired 51 % of the share capital of SOPL on a fully diluted basis. NJ Bio Inc is an antibody-drug conjugate-focused contract research, development, and manufacturing organisation and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and analytical services. SPL acquired 56% of the share capital of NJ Bio Inc on December 20, 2024, for a consideration of Rs 547.96 crore and gained control of NJ Bio Inc as a subsidiary. Key financial Indicators As on/for the period ended March 31 2026 2025 Operatina income Rs crore 2268.55 1256.14 Reported profit after tax (PAT) Rs crore 150.12 264.77 PAT margin % 6.62 21.08 Adjusted debt/adjusted networth Times 0.04 0.25 Interest coverage Times 12.38 35.12 Any other information: Not applicable Note on complexity levels of the rated instrument: Crisil Ratings· complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale. Crisil Ratings will disclose complexity level for all sec [Showing first 8,000 characters — download PDF for full document]